Feng Bo, Pemberton Rachel, Dworakowski Wojciech, Ye Zhengqi, Zetterberg Craig, Wang Guanyu, Morikawa Yoshio, Kumar Sanjeev
Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Boston, Massachusetts (B.F., R.P., W.D., Z.Y., C.Z., G.W., S.K.) and PhoenixBio USA Corporation, New York City, New York (Y.M.)
Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Boston, Massachusetts (B.F., R.P., W.D., Z.Y., C.Z., G.W., S.K.) and PhoenixBio USA Corporation, New York City, New York (Y.M.).
Drug Metab Dispos. 2021 Mar;49(3):254-264. doi: 10.1124/dmd.120.000276. Epub 2020 Dec 29.
The ability to predict human liver-to-plasma unbound partition coefficient (K) is important to estimate unbound liver concentration for drugs that are substrates of hepatic organic anion-transporting peptide (OATP) transporters with asymmetric distribution into the liver relative to plasma. Herein, we explored the utility of PXB chimeric mice with humanized liver that are highly repopulated with human hepatocytes to predict human hepatic disposition of OATP substrates, including rosuvastatin, pravastatin, pitavastatin, valsartan, and repaglinide. In vitro total uptake clearance and transporter-mediated active uptake clearance in C57 mouse hepatocytes were greater than in PXB chimeric mouse hepatocytes for rosuvastatin, pravastatin, pitavastatin, and valsartan. Consistent with in vitro uptake data, enhanced hepatic uptake and resulting total systemic clearance were observed with the above four compounds in severely compromised immune-deficient (SCID) control mice compared with the PXB chimeric mice, which suggest that mouse has a stronger transporter-mediated hepatic uptake than human. In vivo liver-to-plasma K from PXB chimeric and SCID control mice were also compared, and rosuvastatin and pravastatin K in SCID mice were more than 10-fold higher than that in PXB chimeric mice, whereas pitavastatin, valsartan, and repaglinide K in SCID mice were comparable with K in PXB chimeric mice. Finally, PXB chimeric mouse liver-to-plasma K values were compared with the reported human K, and a good correlation was observed as the PXB K vales were within 3-fold of human K Our results indicate that PXB mice could be a useful tool to delineate hepatic uptake and enable prediction of human liver-to-plasma K of hepatic uptake transporter substrates. SIGNIFICANCE STATEMENT: We evaluated PXB mouse with humanized liver for its ability to predict human liver disposition of five organic anion-transporting polypeptide transporter substrates. Both in vitro and in vivo data suggest that mouse liver has a stronger transporter-mediated hepatic uptake than the humanized liver in PXB mouse. More importantly, PXB liver-to-plasma unbound partition coefficient (K) values were compared with the reported human K, and a good correlation was observed. PXB mice could be a useful tool to project human liver-to-plasma K of hepatic uptake transporter substrates.
预测人肝与血浆未结合分配系数(K)的能力对于估算肝有机阴离子转运肽(OATP)转运体底物药物的未结合肝浓度非常重要,这些药物在肝和血浆中的分布不对称。在此,我们研究了用人肝细胞高度重建的人源化肝脏的PXB嵌合小鼠预测OATP底物(包括瑞舒伐他汀、普伐他汀、匹伐他汀、缬沙坦和瑞格列奈)人肝处置的效用。对于瑞舒伐他汀、普伐他汀、匹伐他汀和缬沙坦,C57小鼠肝细胞中的体外总摄取清除率和转运体介导的主动摄取清除率高于PXB嵌合小鼠肝细胞。与体外摄取数据一致,与PXB嵌合小鼠相比,在严重免疫缺陷(SCID)对照小鼠中观察到上述四种化合物的肝摄取增强和由此导致的全身总清除率增加,这表明小鼠的转运体介导的肝摄取比人更强。还比较了PXB嵌合小鼠和SCID对照小鼠的体内肝与血浆K,SCID小鼠中瑞舒伐他汀和普伐他汀的K比PXB嵌合小鼠高10倍以上,而SCID小鼠中匹伐他汀、缬沙坦和瑞格列奈的K与PXB嵌合小鼠中的K相当。最后,将PXB嵌合小鼠的肝与血浆K值与报道的人K值进行比较,观察到良好的相关性,因为PXB K值在人K值的3倍以内。我们的结果表明,PXB小鼠可能是描绘肝摄取并预测肝摄取转运体底物的人肝与血浆K的有用工具。意义声明:我们评估了具有人源化肝脏的PXB小鼠预测五种有机阴离子转运多肽转运体底物人肝处置的能力。体外和体内数据均表明,小鼠肝脏的转运体介导的肝摄取比PXB小鼠中的人源化肝脏更强。更重要的是,将PXB肝与血浆未结合分配系数(K)值与报道的人K值进行比较,观察到良好的相关性。PXB小鼠可能是预测肝摄取转运体底物的人肝与血浆K的有用工具。